STAT+: Pharmalittle: Lilly and Roche are also losers in the Medicare Alzheimer’s decision; former CRO owner pleads guilty to falsifying data

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of Pumpkin Spice for the occasion. Autumn, after all, is only eight months away. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So … here are some items of interest. Have a great day, everyone. …

Medicare may have released a plan to restrict access to the controversial Biogen (BIIB) Alzheimer’s drug, but the biggest losers may actually be other drug makers readying treatments for the debilitating disease, STAT explains. Both Eli Lilly (LLY) and Roche (RHHBY) have such treatments in the works, and Biogen has two more, developed in partnership with Eisai, as well. “While so much of the focus has been on what this means for [the Biogen drug], this recommendation impacts an entire class of drug and is likely to result in a more aligned effort by stakeholders as they try to influence the final version,” said a consultant for drug makers, including Biogen.

Continue to STAT+ to read the full story…

STAT+: Pharmalittle: Lilly and Roche are also losers in the Medicare Alzheimer’s decision; former CRO owner pleads guilty to falsifying data

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top